AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did Celestica Stock Soar 12.68%?
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 29, 2025 6:01 am ET1min read
Aime SummaryOn July 29, 2025, Celestica's stock surged by 12.68% in pre-market trading, driven by a strong second-quarter earnings report that exceeded expectations.
Celestica reported impressive financial results for the second quarter of 2025, with revenue reaching $2.89 billion, a 21% increase from the same period last year. The company's adjusted earnings per share (EPS) also saw a significant rise, up 54% to $1.39. This performance was bolstered by a strong adjusted operating margin of 7.4%, marking a new high for the company. The CEO highlighted strong execution and increased demand, particularly in the Communications sector, as key drivers of this performance.
In addition to its strong financial results,
also raised its annual outlook for 2025. The company now expects revenue of $11.55 billion, up from the previous outlook of $10.85 billion. The adjusted EPS outlook was also increased to $5.50, and the company expects non-GAAP free cash flow of $400 million. These revisions reflect the company's confidence in its continued growth and strong market position.Celestica's performance was driven by its Connectivity & Cloud Solutions (CCS) segment, which saw a 28% revenue increase, and the Advanced Technology Solutions (ATS) segment, which grew by 7%. The company's strong execution and increased demand in key sectors have positioned it well for continued growth in the coming quarters.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet